Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

Chr del(17p)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related tests:

Vysis CLL FISH Probe Kit (2)

Vysis CLL FISH Probe Kit (2)

Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: A1 - Approval venetoclax + ibrutinib Sensitive : A1	venetoclax + ibrutinib Sensitive: A1 - Approval venetoclax + ibrutinib Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + rituximab Sensitive: A2 - Guideline venetoclax + rituximab Sensitive : A2	venetoclax + rituximab Sensitive: A2 - Guideline venetoclax + rituximab Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	pirtobrutinib Sensitive: A2 - Guideline pirtobrutinib Sensitive : A2	pirtobrutinib Sensitive: A2 - Guideline pirtobrutinib Sensitive : A2
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	pirtobrutinib Sensitive: A2 - Guideline pirtobrutinib Sensitive : A2	pirtobrutinib Sensitive: A2 - Guideline pirtobrutinib Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2